Novelion Therapeutics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company reported net revenues of USD 28,669,000. Loss from operations was USD 39,399,000 compared to USD 6,017,000 a year ago. Loss before provision for income taxes was USD 49,247,000 compared to USD 6,051,000 a year ago. Net loss was USD 49,744,000 compared to USD 5,936,000 a year ago. Basic and diluted net loss per common share was USD 2.67 compared to USD 0.56 a year ago. Non-GAAP net loss was USD 16,617,000 compared to USD 14,316,000 a year ago. Non-GAAP net loss per common share - basic was USD 0.89 compared to USD 1.36 a year ago.

For the nine months, the company reported net revenues of USD 99,530,000. Loss from operations was USD 72,834,000 compared to USD 22,346,000 a year ago. Loss before provision for income taxes was USD 101,380,000 compared to USD 33,054,000 a year ago. Net loss was USD 102,142,000 compared to USD 32,950,000 a year ago. Basic and diluted net loss per common share was USD 5.49 compared to USD 3.12 a year ago. Non-GAAP net loss was USD 26,699,000 compared to USD 111,719,000 a year ago. Non-GAAP net loss per common share - basic was USD 1.44 compared to USD 10.57 a year ago.

The company reiterated its previously stated net revenues financial guidance for full year 2017 and expects: total net revenues between USD 135 million and USD 145 million; JUXTAPID net revenues between USD 70 million and USD 75 million; and MYALEPT net revenues between USD 65 million and USD 70 million.